A. Bouvier, Z. Uhry, V. Jooste, A. Drouillard, L. Remontet et al., Focus on an unusual rise in pancreatic cancer incidence in France, Int J Epidemiol, vol.01, issue.6, pp.1764-72, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01541663

, Cancer of the Pancreas -Cancer Stat Facts SEER

T. Conroy, P. Hammel, M. Hebbar, B. Abdelghani, M. Wei et al., FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, N Engl J Med, vol.20, issue.25, pp.2395-406, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02281628

H. Oettle, P. Neuhaus, A. Hochhaus, J. T. Hartmann, K. Gellert et al., Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial, JAMA, vol.310, issue.14, pp.1473-81, 2013.

J. P. Neoptolemos, D. H. Palmer, P. Ghaneh, E. E. Psarelli, J. W. Valle et al., Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial, Lancet Lond Engl, vol.11, pp.1011-1035, 2017.

T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med. 12 mai, vol.364, pp.1817-1842, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00598658

H. A. Burris, M. J. Moore, J. Andersen, M. R. Green, M. L. Rothenberg et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol Off J Am Soc Clin Oncol. juin, vol.15, issue.6, pp.2403-2416, 1997.

V. Hoff, D. D. Ervin, T. Arena, F. P. Chiorean, E. G. Infante et al., Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, vol.369, issue.18, pp.1691-703, 2013.

A. Lièvre, J. Bachet, L. Corre, D. Boige, V. Landi et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res. 15 avr, vol.66, issue.8, pp.3992-3997, 2006.

Y. Bang, E. Van-cutsem, A. Feyereislova, H. C. Chung, L. Shen et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet Lond Engl. 28 août, vol.376, issue.9742, pp.687-97, 2010.

A. Kitts and S. Sherry, The Single Nucleotide Polymorphism Database (dbSNP) of Nucleotide Sequence Variation, National Center for Biotechnology Information (US

L. Dean, . Irinotecan, V. Pratt, H. Mcleod, W. Rubinstein et al., Des recommandations pour prévenir certaines toxicités sévères des chimiothérapies par fluoropyrimidines, Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US, 2012.

X. Ding, W. Chen, H. Fan, and B. Zhu, Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy, Gene. 15 mars, vol.559, issue.1, pp.31-38, 2015.

T. M. Sissung, B. C. English, D. Venzon, W. D. Figg, and J. F. Deeken, Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform, Pharmacogenomics. janv, vol.11, issue.1, pp.89-103, 2010.

Y. Berland, G. Leonetti, . Aix-marseille, and . Universite, , p.100

L. Dahan, J. M. Phelip, L. Malicot, K. Williet, N. Desrame et al., FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX), J Clin Oncol. 20 mai, vol.36, issue.15_suppl, 2018.

M. Whirl-carrillo, E. Mcdonagh, J. Hebert, L. Gong, K. Sangkuhl et al., Pharmacogenomics Knowledge for Personalized Medicine, Clin Pharmacol Ther, vol.92, issue.4, pp.414-421, 2012.

L. P. Martin, T. C. Hamilton, and R. J. Schilder, Platinum resistance: the role of DNA repair pathways, Clin Cancer Res Off J Am Assoc Cancer Res. 1 mars, vol.14, issue.5, pp.1291-1296, 2008.

M. Huang, J. Huang, C. Huang, C. Lin, H. Tsai et al., Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy, World J Surg, vol.41, issue.11, pp.2884-97, 2017.

R. Gao, K. M. Reece, T. Sissung, S. H. Fu, D. J. Venzon et al., Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?, BMJ Open. 3 janv, vol.3, issue.1, 2013.

H. Ma, L. Xu, J. Yuan, M. Shao, Z. Hu et al., Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population, Pharmacogenet Genomics. juin, vol.17, issue.6, pp.417-440, 2007.

N. R. Jones, T. E. Spratt, A. S. Berg, J. E. Muscat, P. Lazarus et al., Association studies of excision repair cross-complementation group 1 (ERCC1) haplotypes with lung and head and neck cancer risk in a Caucasian population, Cancer Epidemiol. avr, vol.35, issue.2, pp.175-81, 2011.

J. Zhu, R. Hua, J. Jiang, L. Zhao, X. Sun et al., Association studies of ERCC1 polymorphisms with lung cancer susceptibility: a systematic review and meta-analysis, PloS One, vol.9, issue.5, p.97616, 2014.

W. Zhou, G. Liu, S. Park, Z. Wang, J. C. Wain et al., Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. févr, vol.14, issue.2, pp.491-497, 2005.

L. Zhang, J. Wang, L. Xu, J. Zhou, X. Guan et al., Nucleotide excision repair gene ERCC1 polymorphisms contribute to cancer susceptibility: a meta-analysis, Mutagenesis. janv, vol.27, issue.1, pp.67-76, 2012.

C. Welsh, R. Day, C. Mcgurk, J. Masters, R. D. Wood et al., Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines, Int J Cancer. 20 juin, vol.110, issue.3, pp.352-61, 2004.

M. Selvakumaran, D. A. Pisarcik, R. Bao, A. T. Yeung, and T. C. Hamilton, Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines, Cancer Res. 15 mars, vol.63, issue.6, pp.1311-1317, 2003.

K. A. Olaussen, A. Dunant, P. Fouret, E. Brambilla, F. André et al., DNA repair by ERCC1 in nonsmall-cell lung cancer and cisplatin-based adjuvant chemotherapy, N Engl J Med. 7 sept, vol.355, issue.10, pp.983-91, 2006.

J. Viguier, V. Boige, C. Miquel, M. Pocard, B. Giraudeau et al., ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer, Clin Cancer Res Off J Am Assoc Cancer Res. 1 sept, vol.11, issue.17, pp.6212-6219, 2005.

V. Boige, J. Mendiboure, J. Pignon, M. Loriot, M. Castaing et al., Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05, J Clin Oncol. 20 mai, vol.28, issue.15, pp.2556-64, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00840582

S. Yu, G. Liu, X. Li, B. Fu, L. Dong et al., Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis, J Cell Biochem, vol.118, issue.12, pp.4782-91, 2017.

E. Giovannetti, P. Pacetti, M. Reni, L. G. Leon, A. Mambrini et al., Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy, Pharmacogenomics. déc, vol.12, issue.12, pp.1641-52, 2011.

A. Strippoli, S. Rossi, M. Martini, M. Basso, D. 'argento et al., ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis, Oncotarget. 27 avr, vol.7, issue.23, pp.35159-68, 2016.

E. Bollschweiler, A. H. Hölscher, T. Herbold, R. Metzger, H. Alakus et al., Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study, Ann Surg, vol.264, issue.5, pp.839-885, 2016.

J. Carles, M. Monzo, M. Amat, S. Jansa, R. Artells et al., Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer, Int J Radiat Oncol Biol Phys, vol.15, issue.4, pp.1022-1052, 2006.

J. Wang, W. Ten-haken, R. K. , C. J. Bi, N. Sadek et al., Use a survival model to correlate singlenucleotide polymorphisms of DNA repair genes with radiation dose-response in patients with non-small cell lung cancer, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.117, issue.1, pp.77-82, 2015.

F. Li, X. Xie, X. Ren, and J. Zhang, A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy, Cancer Chemother Pharmacol, vol.77, issue.6, pp.1183-91, 2016.

V. Boige, C. Mollevi, S. Gourgou, D. Azria, J. Seitz et al., Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial, Int J Cancer, vol.01, issue.11, pp.3163-72, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02421354

C. Pérez-ramírez, M. Cañadas-garre, A. Alnatsha, E. Villar, J. R. Delgado et al., Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients, Pharmacol Res, vol.111, pp.877-84, 2016.

I. Tamai, J. Nezu, H. Uchino, Y. Sai, A. Oku et al., Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family, Biochem Biophys Res Commun. 24 juin, vol.273, issue.1, pp.251-60, 2000.

M. J. Ban, S. H. Ji, C. Lee, S. B. Bae, H. J. Kim et al., Solute carrier organic anion transporter family member 4A1 (SLCO4A1) as a prognosis marker of colorectal cancer, J Cancer Res Clin Oncol. août, vol.143, issue.8, pp.1437-1484, 2017.

C. Pérez-ramírez, M. Cañadas-garre, A. Alnatsha, E. Villar, J. Valdivia-bautista et al., Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients, Pharmacogenomics J, vol.19, issue.2, pp.164-77, 2019.

L. Huang, T. Zhang, C. Xie, X. Liao, Q. Yu et al., SLCO1B1 and SLC19A1 gene variants and irinotecaninduced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer, PloS One, vol.8, issue.10, p.77223, 2013.

A. Khatri, B. W. Williams, J. Fisher, R. C. Brundage, V. J. Gurvich et al., SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours, Br J Cancer. 21 janv, vol.110, issue.2, pp.304-316, 2014.

S. Lee, S. Im, Y. H. Park, S. Y. Woo, S. Kim et al., Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy, Eur J Cancer Oxf Engl, vol.50, issue.4, pp.698-705, 1990.

M. Tanaka, M. Javle, X. Dong, C. Eng, J. L. Abbruzzese et al., Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer, Cancer, vol.15, issue.22, pp.5325-5360, 2010.

, Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients

A. Wong, R. A. Soo, W. Yong, and F. Innocenti, Clinical pharmacology and pharmacogenetics of gemcitabine, Drug Metab Rev. 1 mai, vol.41, issue.2, pp.77-88, 2009.

H. I. Woo, K. Kim, H. Choi, S. Kim, K. Jang et al., Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine, Pharmacogenomics. juill, vol.13, issue.9, pp.1023-1058, 2012.

C. Wang, F. Chen, Y. Liu, Q. Xu, L. Guo et al., Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients, Front Pharmacol, vol.9, p.360, 2018.

M. Harris, K. Bhuvaneshwar, T. Natarajan, L. Sheahan, D. Wang et al., Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine, Pharmacogenet Genomics. févr, vol.24, issue.2, pp.81-93, 2014.

X. Shao, J. Cai, Y. Zheng, J. Wang, J. Feng et al., S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer, Int J Clin Exp Pathol, vol.8, issue.5, pp.5309-5326, 2015.

J. Wang, X. Wang, M. Zhao, S. P. Choo, S. J. Ong et al., Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients, PloS One, vol.9, issue.11, p.111694, 2014.

J. C. Rotondo, S. Bosi, C. Bassi, M. Ferracin, G. Lanza et al., Gene expression changes in progression of cervical neoplasia revealed by microarray analysis of cervical neoplastic keratinocytes, J Cell Physiol. avr, vol.230, issue.4, pp.806-818, 2015.

M. Arbitrio, F. Scionti, E. Altomare, D. Martino, M. T. Agapito et al., Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study, Clin Pharmacol Ther. août, vol.106, issue.2, pp.422-453, 2019.

C. Serdjebi, J. Seitz, J. Ciccolini, M. Duluc, E. Norguet et al., Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen, Pharmacogenomics. juill, vol.14, issue.9, pp.1047-51, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01708020

C. Serdjebi, G. Milano, and J. Ciccolini, Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs, Expert Opin Drug Metab Toxicol. mai, vol.11, issue.5, pp.665-72, 2015.

A. Ruzzo, F. Graziano, F. Galli, F. Galli, E. Rulli et al., Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients, Br J Cancer, vol.117, issue.9, pp.1269-77, 2017.

S. Terrazzino, S. Cargnin, D. Re, M. Danesi, R. Canonico et al., DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis, Pharmacogenomics. août, vol.14, issue.11, pp.1255-72, 2013.

A. M. Lee, Q. Shi, E. Pavey, S. R. Alberts, D. J. Sargent et al., DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147), J Natl Cancer Inst. déc, vol.106, issue.12, 2014.

J. Han, E. S. Shin, Y. Lee, H. Y. Ghang, S. Kim et al., A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer, Pharmacogenomics J. oct, vol.13, issue.5, pp.417-439, 2013.

. Cyp11b1, Liste des gènes étudiés, selon leur fonction Enzymes de phase I : CBR3, vol.2

. Chst10 and . Transporteurs,

. Abcb11, . Slco1a2, . Slco1b1, :. Autres, . Cda et al., , p.1

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, J'informerai les patients des décisions envisagées, de leurs raisons et de

, Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré(e) et méprisé(e) si j'y manque